Roche (RHHBY) News Today $34.96 +0.46 (+1.33%) (As of 12/24/2024 02:38 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartDividendHeadlinesInsider TradesOwnershipShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical BenefitsDecember 19, 2024 | benzinga.comRoche, Prothena miss main goal in mid-stage trial for Parkinson’s drugDecember 19, 2024 | msn.comRoche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s diseaseDecember 19, 2024 | uk.finance.yahoo.comGenentech's Phase IIb Study Of Prasinezumab In Early-Stage Parkinson's Disease Misses Main GoalDecember 19, 2024 | markets.businessinsider.comGenentech's Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson's DiseaseDecember 19, 2024 | businesswire.comRoche's Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson's diseaseDecember 19, 2024 | globenewswire.comF. Hoffmann-La Roche Ltd: Roche transforms mass spectrometry diagnostics with launch of cobas Mass Spec solutionDecember 18, 2024 | finanznachrichten.deRoche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solutionDecember 18, 2024 | globenewswire.comF. Hoffmann-La Roche Ltd: Roche's Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindnessDecember 13, 2024 | finanznachrichten.deRoche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindnessDecember 13, 2024 | finance.yahoo.comRoche Announces Approval Of Vabysmo Prefilled Syringe In The EU - Quick FactsDecember 13, 2024 | markets.businessinsider.comRoche Gets CE Mark For New Molecular Cobas 6800/8800 Systems - Quick FactsDecember 13, 2024 | markets.businessinsider.comRoche's Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindnessDecember 13, 2024 | globenewswire.comRoche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilitiesDecember 13, 2024 | globenewswire.comSaratoga Research & Investment Management Sells 85,311 Shares of Roche Holding AG (OTCMKTS:RHHBY)Saratoga Research & Investment Management cut its stake in shares of Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 3.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,325,810 shares of the company's stock after seDecember 12, 2024 | marketbeat.comNew and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphomaDecember 10, 2024 | globenewswire.comGenentech's Columvi And Lunsumio Data Highlight Potential To Improve Lymphoma OutcomesDecember 10, 2024 | markets.businessinsider.comNew and Updated Data for Genentech's Fixed-Duration Columvi and Lunsumio at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With LymphomaDecember 9, 2024 | businesswire.comRoche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cashDecember 9, 2024 | globenewswire.comFive-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphomaDecember 8, 2024 | uk.finance.yahoo.comFive-Year Results Confirm Genentech’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive LymphomaDecember 8, 2024 | businesswire.comFive-Year Results Confirm Genentech's Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive LymphomaDecember 8, 2024 | businesswire.comFive-year results confirm Roche's Polivy combination therapy as new standard of care for previously untreated aggressive lymphomaDecember 8, 2024 | globenewswire.comFDA Accepts Genentech's Columvi Combo SBLA For R/R Diffuse Large B-Cell Lymphoma TreatmentDecember 5, 2024 | markets.businessinsider.comFDA Accepts Supplemental Biologics License Application for Genentech's Columvi Combination for People With Relapsed or Refractory Diffuse Large B-Cell LymphomaDecember 5, 2024 | businesswire.comFDA accepts supplemental Biologics License Application for Roche's Columvi combination for people with relapsed or refractory diffuse large B-cell lymphomaDecember 5, 2024 | globenewswire.comNVIDIA Invested in These 2 AI Stocks, Should You? (RHHBY)Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution.December 2, 2024 | marketbeat.comPoseida Therapeutics Stock Hits Over 3-Year Highs On Roche’s $1.5B Buyout Deal: Retail Is EuphoricNovember 26, 2024 | msn.comRoche reports SKYSCRAPER-01 study misses primary endpointNovember 26, 2024 | markets.businessinsider.comRoche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: DetailsNovember 26, 2024 | benzinga.comRoche records setback in phase III study of two lung cancer drugsNovember 26, 2024 | reuters.comRoche to acquire US-based Poseida TherapeuticsNovember 26, 2024 | reuters.comRoche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologiesNovember 26, 2024 | globenewswire.comGenentech Reports Update on Phase III SKYSCRAPER-01 Study ResultsNovember 26, 2024 | businesswire.comRoche reports update on Phase III SKYSCRAPER-01 study resultsNovember 26, 2024 | globenewswire.comRoche Gets FDA Approval For First Companion Diagnostic For HER2 Treatment In Biliary Tract CancerNovember 25, 2024 | markets.businessinsider.comRoche receives FDA approval for first companion diagnostic to identify patients with biliary tract cancer eligible for HER2-targeted treatment with ZIIHERANovember 25, 2024 | prnewswire.comNeuron23 Announces Usage of Roche's Digital Biomarker and Device in Parkinson's Disease Clinical TrialNovember 19, 2024 | businesswire.comRoche receives CE Mark for Ventana FOLR1 RxDx AssayNovember 19, 2024 | markets.businessinsider.comRoche's VENTANA FOLR1 (FOLR1-2.1) RxDx Assay Gets CE Mark In Ovarian Cancer TreatmentNovember 18, 2024 | markets.businessinsider.comRoche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERENovember 18, 2024 | prnewswire.comFlare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in OncologyNovember 12, 2024 | prnewswire.comGenentech terminates agreement for Nykode cancer vaccine programNovember 9, 2024 | markets.businessinsider.comGenentech to present blood disorders data at ASHNovember 7, 2024 | markets.businessinsider.comF. Hoffmann-La Roche Ltd: Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024November 5, 2024 | finanznachrichten.deRoche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024November 5, 2024 | globenewswire.comPredicineCARE™ Liquid Biopsy Assay Featured in NEJM as Pivotal Tool in Roche's Phase III Itovebi Breast Cancer TrialNovember 4, 2024 | globenewswire.comAntibody-Drug Conjugates (ADC) Technology Research and Global Markets Report 2024-2025 & 2029 with Profiles of Leading Players - F. Hoffmann-La Roche.November 4, 2024 | globenewswire.comRoche Holding AG (RHHBY) Virtual Neurology Investor Event Conference TranscriptNovember 2, 2024 | seekingalpha.comRoche announces phase III INAVO120 results were publishedNovember 1, 2024 | markets.businessinsider.com Get Roche News Delivered to You Automatically Sign up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter. Email Address liberals FOOLED by Elon’s shocking surprise (Ad)Elon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the liberals broke”... But it turns out that was all just a smokescreen to hide the TRUTH… Click here to discover the real reason Elon Musk became buddy-buddy with Trump. RHHBY Media Mentions By Week RHHBY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RHHBY News Sentiment▼0.020.66▲Average Medical News Sentiment RHHBY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RHHBY Articles This Week▼26▲RHHBY Articles Average Week Get Roche News Delivered to You Automatically Sign up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies China Construction Bank News Airbus News EssilorLuxottica Société anonyme News Iberdrola News Nintendo News Atlas Copco News BNP Paribas News Vinci News Compass Group News Bayerische Motoren Werke Aktiengesellschaft News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:RHHBY) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredBuy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roche Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Roche With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
